MMC Healthcare: Advancing Global Healthcare Through Tradition, Innovation, And Quality Standards
Dr M Padmaja Rani , Director
Acritical pillar of the global healthcare ecosystem, India’s pharmaceutical market is fueled by domestic reforms and a rising demand for accessible healthcare solutions worldwide. The nation’s pandemic-driven leadership in vaccine development coupled with initiatives such as Make in India underscore India’s potential as a pharmaceutical innovation and manufacturing hub. Therein lies an opportunity for Indian pharmaceutical manufacturers to establish themselves in highly regulated international markets. However, they must adhere to stringent regulatory compliance with evolving cGMP guidelines and delayed licensing processes for formulations in certain countries.
Even while manufacturing novel drugs, they must secure investments for research and development, particularly for researching new molecules. Adeptly traversing these challenges is MMC Healthcare (A Suraksha Group Company) with an unwavering focus on quality and patient safety. Suraksha Group consists of Suraksha Pharma, Sumages Pharma, Roorkee Research Labs, Scoat Pharma, Hemp Tribe, SuraX Cosmetics, and Surax Healthcare (USA). The group is vertically integrated into foil printing , pellet manufacturing and strengthened by its in-house analytical testing and research labs.
Ethics in Genetic Constitution
Leveraging its legacy of three generations in pharmaceuticals, nutraceuticals, and cosmetics, MMC Healthcare delivers products across India and more than 20+ countries while focusing on ethical practices and innovation. “We have a pan-India distribution of our brands, and at the same time, we export to different geographies in Asia, Africa, CIS and North America ”, says Dr M. Padmaja Rani, Director, MMC Healthcare. Under the brand of Suraksha, the group offers a wide range of services like manufacturing, marketing, exports, R&D etc. It has an expansive portfolio, producing up to 2000 drug combinations that address critical segments such as psychiatry, diabetes, cardiology, orthopedics, gynecology, and pain management.
The manufacturing operations are run from a NHP-Canada, WHO-GMP-certified Chennai facility equipped with cutting-edge machinery and integrated packaging lines that streamline cost-efficient production. This facility supports various pharmaceutical and nutraceutical products, including innovative offerings like Oral sprays, double-layered diabetic formulations, mouth-dissolving tablets, and sublingual dosage forms.
Ensuring Quality Across Borders
Quality remains non-negotiable across all product lines, whether pharmaceuticals, nutraceuticals, or cosmetics. Every stage of production undergoes rigorous scrutiny, with seven analytical checks conducted from raw materials to the final product. This meticulous approach underscores the company’s dedication to delivering safe and effective healthcare solutions. Guided by a core belief in the sanctity of life, MMC Healthcare embraces its responsibility to uphold the highest standards, ensuring that every product aligns with its principles of protecting and enhancing lives.
To ensure timely product availability across the country, MMC Healthcare's network spans doctors, distributors, and retailers, supported by strategically placed depots across India. It drives pan India operations with a field force of over 100 professionals, promoting more than 500 formulations across key therapeutic areas. The company’s global footprints are in different geographies and have operations in Sri Lanka, Myanmar, Maldives, Cambodia, Kyrgyzstan, Nigeria, Uganda etc., and plans to register 200+ products over the next five years. The group has U.S. office, and promotes a robust portfolio of 15 nutraceutical products under the Ketoveyda brand and Hemp Tribe. The group also has 4 ANDAs and 1 505 (B) 2, developed for the U.S. and Canadian markets.
Tradition Meets Modern Science
As a third-generation business rooted in a legacy of entrepreneurship, MMC Healthcare has steadily expanded its footprint, adapting to opportunities and challenges over the decades. During the early 2000s, amidst the reorganization of states by the central government, the company strategically shifted operations to Uttarakhand. This move proved transformative for the company, enabling the establishment of a comprehensive manufacturing facility that spanned bulk raw material processing, analytical labs, research and development, and packaging materials, effectively creating an integrated production ecosystem. The company is charting a forward-looking growth trajectory, driven by meticulous planning and a positive vision for the future.
With India’s abundant natural resources and a rich history in Ayurveda, it envisions leveraging indigenous herbs to create innovative, natural products. One of the notable innovations is its work with Cannabis sativa, commonly known as Hemp. Leveraging Uttarakhand’s progressive licensing framework for cultivating cannabis plants, MMC Healthcare undertook extensive clinical research to develop a Hemp Tribe product line launched in February 2024. Driven by a commitment to delivering quality products and fostering sustainable growth, the company can play a pivotal role in advancing the pharmaceutical and allied industries in India.
A particular focus lies in exploring plant-based solutions for many acute and chronic diseases, where MMC Healthcare aims to deepen its contributions to the global healthcare landscape. Dr Padmaja believes that blending traditional knowledge with modern science can unlock the potential of natural remedies for wider global applications. In addition, the company aspires to penetrate regulated international markets, ensuring its products, developed with meticulous care and attention, are embraced globally. This ambition is backed by a commitment to scaling up research facilities, enhancing contract research capabilities, and strengthening analytical labs. As the world increasingly focuses on the Make in India initiative, MMC Healthcare believes in further advancing domestic capabilities in research, development, and raw material production to strengthen India’s leadership in the global pharmaceutical landscape.
Even while manufacturing novel drugs, they must secure investments for research and development, particularly for researching new molecules. Adeptly traversing these challenges is MMC Healthcare (A Suraksha Group Company) with an unwavering focus on quality and patient safety. Suraksha Group consists of Suraksha Pharma, Sumages Pharma, Roorkee Research Labs, Scoat Pharma, Hemp Tribe, SuraX Cosmetics, and Surax Healthcare (USA). The group is vertically integrated into foil printing , pellet manufacturing and strengthened by its in-house analytical testing and research labs.
Ethics in Genetic Constitution
Leveraging its legacy of three generations in pharmaceuticals, nutraceuticals, and cosmetics, MMC Healthcare delivers products across India and more than 20+ countries while focusing on ethical practices and innovation. “We have a pan-India distribution of our brands, and at the same time, we export to different geographies in Asia, Africa, CIS and North America ”, says Dr M. Padmaja Rani, Director, MMC Healthcare. Under the brand of Suraksha, the group offers a wide range of services like manufacturing, marketing, exports, R&D etc. It has an expansive portfolio, producing up to 2000 drug combinations that address critical segments such as psychiatry, diabetes, cardiology, orthopedics, gynecology, and pain management.
The manufacturing operations are run from a NHP-Canada, WHO-GMP-certified Chennai facility equipped with cutting-edge machinery and integrated packaging lines that streamline cost-efficient production. This facility supports various pharmaceutical and nutraceutical products, including innovative offerings like Oral sprays, double-layered diabetic formulations, mouth-dissolving tablets, and sublingual dosage forms.
“As a third-generation business rooted in a legacy of entrepreneurship, MMC Healthcare has steadily expanded its footprint, adapting to opportunities and challenges over the decades
Ensuring Quality Across Borders
Quality remains non-negotiable across all product lines, whether pharmaceuticals, nutraceuticals, or cosmetics. Every stage of production undergoes rigorous scrutiny, with seven analytical checks conducted from raw materials to the final product. This meticulous approach underscores the company’s dedication to delivering safe and effective healthcare solutions. Guided by a core belief in the sanctity of life, MMC Healthcare embraces its responsibility to uphold the highest standards, ensuring that every product aligns with its principles of protecting and enhancing lives.
To ensure timely product availability across the country, MMC Healthcare's network spans doctors, distributors, and retailers, supported by strategically placed depots across India. It drives pan India operations with a field force of over 100 professionals, promoting more than 500 formulations across key therapeutic areas. The company’s global footprints are in different geographies and have operations in Sri Lanka, Myanmar, Maldives, Cambodia, Kyrgyzstan, Nigeria, Uganda etc., and plans to register 200+ products over the next five years. The group has U.S. office, and promotes a robust portfolio of 15 nutraceutical products under the Ketoveyda brand and Hemp Tribe. The group also has 4 ANDAs and 1 505 (B) 2, developed for the U.S. and Canadian markets.
Tradition Meets Modern Science
As a third-generation business rooted in a legacy of entrepreneurship, MMC Healthcare has steadily expanded its footprint, adapting to opportunities and challenges over the decades. During the early 2000s, amidst the reorganization of states by the central government, the company strategically shifted operations to Uttarakhand. This move proved transformative for the company, enabling the establishment of a comprehensive manufacturing facility that spanned bulk raw material processing, analytical labs, research and development, and packaging materials, effectively creating an integrated production ecosystem. The company is charting a forward-looking growth trajectory, driven by meticulous planning and a positive vision for the future.
With India’s abundant natural resources and a rich history in Ayurveda, it envisions leveraging indigenous herbs to create innovative, natural products. One of the notable innovations is its work with Cannabis sativa, commonly known as Hemp. Leveraging Uttarakhand’s progressive licensing framework for cultivating cannabis plants, MMC Healthcare undertook extensive clinical research to develop a Hemp Tribe product line launched in February 2024. Driven by a commitment to delivering quality products and fostering sustainable growth, the company can play a pivotal role in advancing the pharmaceutical and allied industries in India.
A particular focus lies in exploring plant-based solutions for many acute and chronic diseases, where MMC Healthcare aims to deepen its contributions to the global healthcare landscape. Dr Padmaja believes that blending traditional knowledge with modern science can unlock the potential of natural remedies for wider global applications. In addition, the company aspires to penetrate regulated international markets, ensuring its products, developed with meticulous care and attention, are embraced globally. This ambition is backed by a commitment to scaling up research facilities, enhancing contract research capabilities, and strengthening analytical labs. As the world increasingly focuses on the Make in India initiative, MMC Healthcare believes in further advancing domestic capabilities in research, development, and raw material production to strengthen India’s leadership in the global pharmaceutical landscape.
🍪 Do you like Cookies?
We use cookies to ensure you get the best experience on our website. Read more...